Mariner’s Zenas BioPharma ZBIO Stock Holding History

Mariner’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,676	Closed	-$279K	–	3881
2025 Q4	$279K	Buy	+7,676	New	+$252K	﹤0.01%	2908

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Mariner's ZBIO Position: Q1 2026 in Review

Mariner sold out of Zenas BioPharma (ZBIO) in Q1 2026, closing a stake of 7,676 shares — an estimated $279K sold.

Mariner first reported a position in ZBIO in Q4 2025 and held it in 1 quarter. The position peaked at $279K in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

Mariner reported no remaining Zenas BioPharma position as of Q1 2026 after selling out during the quarter.
Mariner sold 7,676 Zenas BioPharma shares in Q1 2026, an estimated $279K.
Mariner first reported a position in Zenas BioPharma in Q4 2025 and held it in 1 quarter.
Mariner's Zenas BioPharma position peaked at $279K in Q4 2025.
139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.